State Street Corp Raises Stock Position in Immunic, Inc. (NASDAQ:IMUX)

State Street Corp raised its holdings in shares of Immunic, Inc. (NASDAQ:IMUX) by 7.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 167,145 shares of the company’s stock after purchasing an additional 11,642 shares during the period. State Street Corp’s holdings in Immunic were worth $276,000 at the end of the most recent quarter.

Separately, Connor Clark & Lunn Investment Management Ltd. raised its stake in Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares during the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Immunic

In other Immunic news, Director Richard Alan Rudick bought 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the transaction, the director now directly owns 87,300 shares of the company’s stock, valued at approximately $100,395. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on IMUX shares. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 target price on shares of Immunic in a report on Monday, September 9th. Leerink Partnrs raised Immunic to a “strong-buy” rating in a report on Monday, September 9th. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Finally, HC Wainwright began coverage on Immunic in a research report on Monday, November 25th. They set a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $11.80.

Immunic Price Performance

Shares of NASDAQ:IMUX opened at $1.10 on Friday. Immunic, Inc. has a 1 year low of $0.97 and a 1 year high of $2.11. The firm has a market capitalization of $99.09 million, a PE ratio of -0.89 and a beta of 1.89. The business’s 50 day moving average price is $1.15 and its 200-day moving average price is $1.32.

Immunic Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.